April 9, 2019 07:02 AM EDT
Deals

It’s a sell­er’s world in biotech M&A, and No­var­tis CEO Vas Narasimhan has his check book out and pen ready

John Carroll

Editor & Founder

The Al­con spin­off is of­fi­cial­ly done to­day, de­but­ing on the Swiss ex­change with a mar­ket cap of $25 bil­lion-plus, and No­var­tis CEO Vas Narasimhan is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times